Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 07, 2012 ) New York, NY -- As discussed by VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, the current share price slide by shares of Synergy Pharmaceuticals (SGYP) could have opened up quite the buying opportunity for investors paying attention.
Shares of Synergy Pharmaceuticals (SGYP) have slipped over the past couple of weeks and are again trading at levels under the four dollar mark, prices not seen in many months beforehand. With key catalysts pending for this company later in the year and with a product in the late stages of development that could be worth billions over the long run on the open market, SGYP could be trading for quite the relative bargain at the current time. As the year progresses and the significant trial catalyst draws nearer, Synergy could be gearing up for a reversal from the current downtrend.
Also encouraging, Synergy secured a key merger agreement last month with Callisto Pharmaceuticals (CLSP) that wholly boosts the company's short and long term potential. For months investors had been wondering when the SGYP market cap would begin to approach that of competitor Ironwood Pharmaceuticals (IRWD), which sits at well over a billion dollars, since Synergy's Plecanatide has proven thus far in studies to have a superior side effect profile to Ironwood's Linaclotide, which is currently before the FDA for approval review.
The Callisto/Synergy merger opens the door for an equalization in market cap, and while prices are depressed, big players may see the opporunity to jump in.
For the full VFC's Stock House report, visit: http://vfcsstockhouse.com/blog/article/-synergy-pharmaceuticals-a-buying-opportunity-now-that-could-pay-off-nicely-later
For a full list of this week's hot stocks to watch visit: http://vfcsstockhouse.com/blog/article/-weekly-stock-watch-week-of-august-6-imsc-amrn-ssh-lptn-mric-sgyp-trov-ctso-celh-irwd-bsx-si-pfe-hgsi-gsk-dndn-fsx-clsp-fb-znga-ge-jcp-dis-m
Contact VFC's Stock House: vfc@vfcsstockhouse.com
Originally published at: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|